Correction: Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin

Correction on: Qian J, Cheng W, Li S, Deng L, Gao D, Zhang X and Zhang Y (2026) Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin. Front. Pharmacol. 16:1727729. doi: 10.3389/fphar.2025.1727729 Wrong content There was a mistake in figure [Figure 2F,2G; Figure 3D (bar graph for cell lines H358 and H1299); Figure6 A, 6D] as published. The compound name "Rhoifolin" was incorrectly spelled as "Phoifolin". There was a mistake in figure [Figure 2B] as published. The legend label for the "48 h" time point was incorrectly written as "48 4" . There was a mistake in figure [Figure 3D ] as published. The asterisks indicating statistical significance on the bar graph were omitted. The corrected Figure 2,Figure 3 and Figure 6 appears below. The original version of this article has been updated.Reminder: Figures, tables, and images will be published under a Creative Commons CC-BY license and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.